BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1455 related articles for article (PubMed ID: 28847469)

  • 1. T-cell therapy for chronic viral hepatitis.
    Bertoletti A; Tan AT; Koh S
    Cytotherapy; 2017 Nov; 19(11):1317-1324. PubMed ID: 28847469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Chronic Hepatitis B Virus Infection.
    Bertoletti A; Le Bert N
    Gut Liver; 2018 Sep; 12(5):497-507. PubMed ID: 29316747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B Gene Therapy Coming to Age.
    Soriano V
    AIDS Rev; 2018; 20(2):125-127. PubMed ID: 29938706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8+ T-Cell Responses in Hepatitis B and C: The (HLA-) A, B, and C of Hepatitis B and C.
    Nitschke K; Luxenburger H; Kiraithe MM; Thimme R; Neumann-Haefelin C
    Dig Dis; 2016; 34(4):396-409. PubMed ID: 27170395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD8
    Zhang Y; Wu Y; Deng M; Xu D; Li X; Xu Z; Hu J; Zhang H; Liu K; Zhao Y; Gao F; Bi S; Gao GF; Zhao J; Liu WJ; Meng S
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunopathology of chronic liver diseases].
    Meyer zum Büschenfelde KH
    Verh Dtsch Ges Pathol; 1995; 79():186-97. PubMed ID: 8600684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation.
    Fontaine H; Alric L; Labreuche J; Legendre B; Louvet A; Antoine C; Legendre CM; Hazzan M; Kamar N; Dharancy S; Pol S; Duhamel A; Mathurin P
    J Hepatol; 2019 May; 70(5):831-838. PubMed ID: 30879789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming CD8+ T-Cell Exhaustion in Viral Hepatitis: Lessons from the Mouse Model and Clinical Perspectives.
    Wieland D; Hofmann M; Thimme R
    Dig Dis; 2017; 35(4):334-338. PubMed ID: 28468011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of HIV and hepatitis virus coinfection.
    Mendes-Corrêa M; Núñez M
    Expert Opin Pharmacother; 2010 Oct; 11(15):2497-516. PubMed ID: 20629586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular virology of chronic hepatitis B and C: parallels, contrasts and impact on drug development and treatment outcome.
    Delaney WE
    Antiviral Res; 2013 Jul; 99(1):34-48. PubMed ID: 23602852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.
    Godon O; Evlachev A; Bourgine M; Meritet JF; Martin P; Inchauspe G; Michel ML
    Vaccine; 2015 Aug; 33(36):4548-53. PubMed ID: 26209840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonlytic Lymphocytes Engineered to Express Virus-Specific T-Cell Receptors Limit HBV Infection by Activating APOBEC3.
    Koh S; Kah J; Tham CYL; Yang N; Ceccarello E; Chia A; Chen M; Khakpoor A; Pavesi A; Tan AT; Dandri M; Bertoletti A
    Gastroenterology; 2018 Jul; 155(1):180-193.e6. PubMed ID: 29550589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward Curative Immunomodulation Strategies for Chronic Hepatitis B Virus Infection.
    Zhu W; Liu H; Zhang X
    ACS Infect Dis; 2019 May; 5(5):703-712. PubMed ID: 30907080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of HBV-Specific CD8
    Heim K; Neumann-Haefelin C; Thimme R; Hofmann M
    Front Immunol; 2019; 10():2240. PubMed ID: 31620140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus: from diagnosis to treatment.
    Dény P; Zoulim F
    Pathol Biol (Paris); 2010 Aug; 58(4):245-53. PubMed ID: 20580167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection.
    Meng Z; Chen Y; Lu M
    Front Immunol; 2019; 10():3127. PubMed ID: 32117201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory receptor molecules in chronic hepatitis B and C infections: novel targets for immunotherapy?
    Hakim MS; Spaan M; Janssen HL; Boonstra A
    Rev Med Virol; 2014 Mar; 24(2):125-38. PubMed ID: 24757728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver-directed gamma interferon gene delivery in chronic hepatitis C.
    Shin EC; Protzer U; Untergasser A; Feinstone SM; Rice CM; Hasselschwert D; Rehermann B
    J Virol; 2005 Nov; 79(21):13412-20. PubMed ID: 16227262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
    Kawagishi N; Suda G; Onozawa M; Kimura M; Maehara O; Ohara M; Izumi T; Umemura M; Ito J; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
    J Viral Hepat; 2017 Dec; 24(12):1098-1106. PubMed ID: 28632923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.